INITIAL combination therapy with vildagliptin/metformin in drug-naive Asian type 2 diabetes patients: influence of age, BMI and co-morbidities in a real world setting

被引：0
|
作者：
Mirasol, R. C. [1 ]
Pathan, M. F. [2 ]
Chawla, M. [3 ]
Kim, T. H. [4 ]
Cooke, K. [5 ]
Hours-Zesiger, P. [5 ]
Shete, A. [5 ]
机构：
[1] St Lukes Med Ctr, Quezon City, Philippines
[2] BIRDEM Hosp, Dhaka, Bangladesh
[3] LINA Diabet Care Ctr, Mumbai, Maharashtra, India
[4] Seoul Med Ctr, Seoul, South Korea
[5] Novartis Pharma AG, Basel, Switzerland
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
774
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [31] The Safety and Tolerability of Metformin plus Colesevelam in Drug-Naive Patients with Early Type 2 Diabetes Mellitus
    Abby, Stacey L.
    Garvey, W. Timothy
    Handelsman, Yehuda
    Fonseca, Vivian A.
    Goldberg, Ronald B.
    Rosenstock, Julio
    Jones, Michael R.
    Markiewicz, Magdalena
    Jin, Xiaoping
    Misir, Soamnauth
    Nagendran, Sukumar
    DIABETES, 2010, 59 : A173 - A173
  • [32] Effect of Combination Therapy with Alogliptin and Pioglitazone in Drug-Naive Patients with Type 2 Diabetes on β-Cell Function and Insulin Resistance
    Inzucchi, Silvio E.
    Rosenstock, Julio
    Seufert, Jochen
    Fleck, Penny
    Wilson, Craig
    Mekki, Qais
    DIABETES, 2009, 58 : A520 - A520
  • [33] Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study
    Chatterjee, Sanjay
    Chatterjee, Sudip
    JOURNAL OF DIABETES, 2014, 6 (03) : 237 - 242
  • [34] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin versus pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Liu, G.
    Lee, M. A.
    Sisk, C. McCrary
    Williams-Herman, D. E.
    Kaufman, K. D.
    Goldstein, B. J.
    DIABETOLOGIA, 2010, 53
  • [35] Vildagliptin decreases postprandial chylomicron triglycerides (TGs) in drug-naive patients with type 2 diabetes (T2DM)
    Matikainen, Niina
    Manttari, Sakari
    Schweizer, Anja
    Ulvestad, Anne
    Mills, David
    Dunning, Beth E.
    Foley, James E.
    Taskinen, Marja-Riitta
    DIABETES, 2006, 55 : A125 - A125
  • [36] Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naive Patients with Type 2 Diabetes
    Kadoglou, N. P. E.
    Kapelouzou, A.
    Tsanikidis, H.
    Vitta, I.
    Liapis, C. D.
    Sailer, N.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (02) : 63 - 68
  • [37] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Lee, M. A.
    Sisk, C. M.
    Williams-Herman, D. E.
    Engel, S. S.
    Kaufman, K. D.
    Goldstein, B. J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) : 930 - 938
  • [38] Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study
    Pratley, R. E.
    Fleck, P.
    Wilson, C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 613 - 621
  • [39] Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    Bosi, E.
    Dotta, F.
    Jia, Y.
    Goodman, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 506 - 515
  • [40] Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study
    Mohan, Viswanathan
    Zargar, Abdul
    Chawla, Manoj
    Joshi, Ameya
    Ayyagari, Usha
    Sethi, Bipin
    Gaurav, Kumar
    Patted, Usha Rani H.
    Bhagat, Seema Vikas
    Mane, Amey Ishwara
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 2925 - 2933
12345